{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Skin+Cancer&page=18", "query": { "condition": "Metastatic Skin Cancer", "page": 18 }, "page_size": 10 }, "pagination": { "page": 18, "page_size": 10, "total_count": 2838, "total_pages": 284, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Skin+Cancer&page=19&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Skin+Cancer&page=17&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-15T13:31:12.121Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02734290", "title": "Standard of Care Chemotherapy Plus Pembrolizumab for Breast Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Triple Negative Breast Cancer" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Capecitabine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Providence Health & Services", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 29, "start_date": "2016-02-23", "completion_date": "2026-12", "has_results": true, "last_update_posted_date": "2026-04-24", "last_synced_at": "2026-11-15T13:31:12.121Z", "location_count": 2, "location_summary": "Los Angeles, California • Portland, Oregon", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT02734290" }, { "nct_id": "NCT01111825", "title": "Temsirolimus Plus Neratinib for Patients With Metastatic HER2-Amplified or Triple Negative Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Breast Cancer" ], "interventions": [ { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Neratinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Puma Biotechnology, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 99, "start_date": "2010-04", "completion_date": "2016-07", "has_results": true, "last_update_posted_date": "2018-09-26", "last_synced_at": "2026-11-15T13:31:12.121Z", "location_count": 4, "location_summary": "Goodyear, Arizona • Los Angeles, California • New York, New York", "locations": [ { "city": "Goodyear", "state": "Arizona" }, { "city": "Los Angeles", "state": "California" }, { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01111825" }, { "nct_id": "NCT00615940", "title": "Combination of Oral WX-671 Plus Capecitabine vs. Capecitabine Monotherapy in First-line Her2-negative Metastatic Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Breast Cancer" ], "interventions": [ { "name": "WX-671", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Heidelberg Pharma AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 132, "start_date": "2008-07", "completion_date": "2012-04", "has_results": false, "last_update_posted_date": "2014-02-28", "last_synced_at": "2026-11-15T13:31:12.121Z", "location_count": 3, "location_summary": "New York, New York • Cleveland, Ohio • Philadelphia, Pennsylvania", "locations": [ { "city": "New York", "state": "New York" }, { "city": "Cleveland", "state": "Ohio" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00615940" }, { "nct_id": "NCT01281150", "title": "Veliparib in Combination With Carboplatin and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Adult Solid Neoplasm", "Estrogen Receptor Negative", "Estrogen Receptor Positive", "HER2/Neu Negative", "Male Breast Carcinoma", "Progesterone Receptor Negative", "Recurrent Breast Carcinoma", "Stage IIIB Breast Cancer", "Stage IIIC Breast Cancer", "Stage IV Breast Cancer", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Carboplatin", "type": "DRUG" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Veliparib", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 22, "start_date": "2011-01", "completion_date": null, "has_results": false, "last_update_posted_date": "2015-05-25", "last_synced_at": "2026-11-15T13:31:12.121Z", "location_count": 3, "location_summary": "Hershey, Pennsylvania • Pittsburgh, Pennsylvania", "locations": [ { "city": "Hershey", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01281150" }, { "nct_id": "NCT05877430", "title": "Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "NSCLC", "HNSCC", "Melanoma", "Metastatic Cancer", "Advanced Solid Tumor", "Advanced Cancer" ], "interventions": [ { "name": "CJRB-101", "type": "DRUG" }, { "name": "Pembrolizumab injection", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "CJ Bioscience, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 160, "start_date": "2023-09-11", "completion_date": "2027-10", "has_results": false, "last_update_posted_date": "2024-12-20", "last_synced_at": "2026-11-15T13:31:12.121Z", "location_count": 2, "location_summary": "Irvine, California • Pittsburgh, Pennsylvania", "locations": [ { "city": "Irvine", "state": "California" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT05877430" }, { "nct_id": "NCT00991991", "title": "Study of Tumor Tissue Samples From Patients With Stage I, Stage II, or Stage III Malignant Melanoma", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Melanoma (Skin)" ], "interventions": [ { "name": "gene expression analysis", "type": "GENETIC" }, { "name": "polymerase chain reaction", "type": "GENETIC" }, { "name": "polymorphism analysis", "type": "GENETIC" }, { "name": "matrix-assisted laser desorption/ionization time of flight mass spectrometry", "type": "OTHER" }, { "name": "medical chart review", "type": "OTHER" } ], "intervention_types": [ "GENETIC", "OTHER" ], "sponsor": "Case Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 5, "start_date": "2009-07", "completion_date": "2016-03", "has_results": false, "last_update_posted_date": "2016-05-17", "last_synced_at": "2026-11-15T13:31:12.121Z", "location_count": 1, "location_summary": "Cleveland, Ohio", "locations": [ { "city": "Cleveland", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT00991991" }, { "nct_id": "NCT00650910", "title": "Study To Examine The Effects Of Lapatinib On The Pharmacokinetics Of Digoxin In Subjects w/ ErbB2 Positive Breast Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neoplasms, Breast" ], "interventions": [ { "name": "lapatinib", "type": "DRUG" }, { "name": "Digoxin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 17, "start_date": "2008-04-23", "completion_date": "2009-07-10", "has_results": false, "last_update_posted_date": "2017-11-17", "last_synced_at": "2026-11-15T13:31:12.121Z", "location_count": 1, "location_summary": "Albuquerque, New Mexico", "locations": [ { "city": "Albuquerque", "state": "New Mexico" } ], "official_url": "https://clinicaltrials.gov/study/NCT00650910" }, { "nct_id": "NCT06635980", "title": "Hypofractionated Radiotherapy Before or After Breast Surgery for Treatment of Patients With Non-Metastatic Breast Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anatomic Stage I Breast Cancer AJCC v8", "Anatomic Stage II Breast Cancer AJCC v8", "Anatomic Stage III Breast Cancer AJCC v8", "Breast Carcinoma", "Triple-Negative Breast Carcinoma" ], "interventions": [ { "name": "Biopsy of Breast", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Breast Surgery", "type": "PROCEDURE" }, { "name": "Chemotherapy", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Contrast Enhanced Digital Mammography", "type": "PROCEDURE" }, { "name": "Hypofractionated Radiation Therapy", "type": "RADIATION" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Survey Administration", "type": "OTHER" }, { "name": "Tissue Collection", "type": "PROCEDURE" }, { "name": "Ultrasound Imaging", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE", "DRUG", "RADIATION", "OTHER" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 120, "start_date": "2025-05-14", "completion_date": "2034-10-21", "has_results": false, "last_update_posted_date": "2026-09-03", "last_synced_at": "2026-11-15T13:31:12.121Z", "location_count": 1, "location_summary": "Scottsdale, Arizona", "locations": [ { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT06635980" }, { "nct_id": "NCT03955640", "title": "Hyperthermia and Olaparib in Treating Breast Cancer Patients With Chest Wall Recurrences", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Metastatic Malignant Neoplasm in the Chest Wall", "Recurrent Breast Carcinoma" ], "interventions": [ { "name": "Olaparib", "type": "DRUG" }, { "name": "Hyperthermia Treatment", "type": "PROCEDURE" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" } ], "intervention_types": [ "DRUG", "PROCEDURE", "OTHER" ], "sponsor": "Thomas Jefferson University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "FEMALE", "summary": "18 Years to 80 Years · Female only" }, "enrollment_count": 3, "start_date": "2019-05-20", "completion_date": "2021-08-26", "has_results": false, "last_update_posted_date": "2025-12-22", "last_synced_at": "2026-11-15T13:31:12.121Z", "location_count": 1, "location_summary": "Philadelphia, Pennsylvania", "locations": [ { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03955640" }, { "nct_id": "NCT03972046", "title": "Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Melanoma (Skin)", "Melanoma Stage IIIb-IVM1a", "Metastasis Skin", "Tumor Skin", "BRAF Gene Mutation" ], "interventions": [ { "name": "Talimogene laherparepvec (T-Vec)", "type": "DRUG" }, { "name": "Dabrafenib (BRAF Inhibitor)", "type": "DRUG" }, { "name": "Trametinib (MEK Inhibitor)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TriHealth Inc.", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-06-24", "completion_date": "2020-02-03", "has_results": false, "last_update_posted_date": "2020-10-19", "last_synced_at": "2026-11-15T13:31:12.121Z", "location_count": 1, "location_summary": "Cincinnati, Ohio", "locations": [ { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT03972046" } ] }